46 completed, 3 terminated, 3 unknown, 3 withdrawn. 21 Phase 4, 18 Phase 3, 7 Not applicable, 3 Phase 1, 3 Phase 2.
Follow Ezetimibe, Simvastatin Drug Combination: new trials by email Literature Review of Ezetimibe, Simvastatin Drug Combination trials Research Report on Ezetimibe, Simvastatin Drug Combination
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer Vytorin, Ezetimibe - Prostate Cancer | Phase 2 | Recruiting | Cedars-Sinai Medical Center | 140 | 2024-07-16 | 2026-03-11 |
| A Study of the PK Interaction of CXA-10 With Pravastatin and Vytorin® in Healthy Males CXA-10, pravastatin, Vytorin® (combination of simvastatin and ezetimibe) - Acute Kidney Injury | Phase 1 | Completed | Complexa, Inc. | 10 | 2015-12-01 | 2016-05-03 |
| Cellular Effect of Cholesterol-Lowering Prior to Prostate Removal ezetimibe 10mg-simvastatin 40mg - Prostate Cancer | Early Phase 1 | Completed | Cedars-Sinai Medical Center | 63 | 2015-09-01 | 2023-02-22 |
| Efficacy and Safety of Simvastatin-ezetimibe Combination Therapy Among Patients With SLE Ezetimibe+Simvastatin Drug Combination - Atherosclerosis | Early Phase 1 | Unknown | Peking Union Medical College Hospital | 30 | 2015-04-01 | 2015-09-14 |
| Efficacy/Safety of Rosuvastatin+Ezetimibe in High Risk Patients With Primary Hypercholesterolemia/Mixed Dyslipidemia Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according to clinical evaluation., Simvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according to clinical evaluation. - Hypercholesterolemia, Dyslipidemia | Phase 3 | Completed | Ache Laboratorios Farmaceuticos S.A. | 129 | 2013-03-01 | 2020-01-22 |
| A Study to Evaluate the Efficacy and Safety of Vytorin Versus Standard Treatment of Other Statins in Moderate, Moderately High and High Risk Participants (MK-0653A-406) Ezetimibe/simvastatin, Other Statin - Dyslipidemia | Phase 4 | Withdrawn | Organon and Co | 2013-03-01 | 2022-02-18 | |
| Statins for Oxidative Stress and Mitochondrial Function in Diabetic Polyneuropathy calcined magnesia, Ezetimibe/simvastatin, Rosuvastatin - Oxidative Stress, Diabetic Polyneuropathy | Phase 2 | Completed | University of Guadalajara | 74 | 2012-02-01 | 2014-05-06 |
| Vascular and Metabolic Effects of Vytorin vs Simvastatin placebo, vytorin, simvastatin - Hypercholesterolemia | Phase 4 | Completed | Gachon University Gil Medical Center | 204 | 2011-11-01 | 2014-11-04 |
| Effects on Atherosclerosis Regression of Ezetimibe or Ezetimibe Plus Simvastatin; Evaluated by Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Ezetrol (Ezetimibe), Vytorin (Ezetimibe + Simvastatin) - Atherosclerosis | Not applicable | Withdrawn | Korea University | 2011-09-01 | 2015-03-18 | |
| Vascular and Metabolic Effects of Vytorin placebo, vytorin - Hypercholesterolemia | Phase 4 | Completed | Gachon University Gil Medical Center | 204 | 2011-07-01 | 2014-11-04 |
| Vytorin in the Treatment of Alopecia Areata vytorin - Alopecia Areata | Phase 1 | Completed | University of Miami | 29 | 2011-07-01 | 2015-03-17 |
| To Study the Effect of Vytorin on Intracellular Lipid and Inflammation in Obese Subjects Vytorin, Placebo - Inflammation | Not applicable | Completed | University at Buffalo | 20 | 2011-05-01 | 2024-04-17 |
| Study to Compare the Effect of Vytorin (Simvastatin/Ezetimibe) 10/20mg Versus Atorvastatin 20mg on ApoB/ApoA1 Ratio in Subjects With Diabetes simvastatin/ezetimibe, atorvastatin 20mg - Type 2 Diabetes Mellitus Without Insulin Treatment | Phase 4 | Unknown | Seoul National University Hospital | 132 | 2010-09-01 | 2010-08-19 |
| Pleiotropism of Statin Therapy in High Dose Versus Low Dose Combined With Ezetimibe simvastatin, combined with simvastatin ezetimibe, placebo - Endothelial Function | Not applicable | Unknown | Federal University of Bahia | 60 | 2010-03-01 | 2010-11-16 |
| Efficacy of Ezetimibe/Simvastatin 10/20 mg and MK0524A (1-2 g/Day) in Mixed Hyperlipidemia and Two or More Risk Factors ezetimibe/simvastatin 10/20 mg + placebo, ezetimibe/simvastatin 10/20 mg + MK0524A - Cardiovascular Diseases, Hyperlipidemia | Phase 4 | Withdrawn | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | 2009-11-01 | 2015-03-24 | |
| Additive Effect of Ezetimibe Upon Simvastatin During Myocardial Infarction Simvastatin, Ezetimibe-Simvastatin - Myocardial Infarction | Phase 4 | Completed | Brasilia Heart Study Group | 40 | 2009-05-01 | 2010-03-24 |
| The PostprAndial eNdothelial Function After Combination of Ezetimibe and simvAstatin Study Simvastatin, Simvastatin/Ezetimibe - Metabolic Syndrome | Phase 4 | Completed | dr.Frank L.J. Visseren | 100 | 2009-04-01 | 2013-01-09 |
| Ezetimibe/Simvastatin (MK-0653A) Versus Rosuvastatin Versus Doubling Statin Dose in Participants With Cardiovascular Disease and Diabetes Mellitus (MK-0653A-133)(COMPLETED) ezetimibe (+) simvastatin, simvastatin 40 mg or atorvastatin 20 mg, Rosuvastatin - Cardiovascular Disorder, Diabetes Mellitus | Phase 3 | Completed | Organon and Co | 808 | 2009-04-01 | 2024-05-16 |
| Simvastatin With or Without Ezetimibe and Atherothrombotic Biomarker Assessment simvastatin, ezetimibe/simvastatin - Metabolic Syndrome | Phase 4 | Completed | University of Maryland, Baltimore | 15 | 2009-01-01 | 2020-01-14 |
| Effects of Simvastatin and Ezetimibe on Cardiovascular Risk Markers in Patients With Dyslipidemia Simvastatin, Ezetimibe, Simvastatin + Ezetimibe - Dyslipidemia | Not applicable | Completed | Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana | 42 | 2009-01-01 | 2018-03-08 |
Showing 20 of 56. Sign in to see all of them.
Hypercholesterolemia (22) · Atherosclerosis (11) · Cardiovascular Diseases (6) · Dyslipidemias (5) · Hyperlipidemias (5) · Metabolic Syndrome (5) · Inflammation (4) · Diabetes Mellitus (3) · Angina Pectoris (2) · Hyperlipoproteinemia Type II (2) · Hypertension (2) · Insulin Resistance (2) · Myocardial Infarction (2) · Peripheral Arterial Disease (2) · Prostatic Neoplasms (2)
Organon and Co (24) · Cedars-Sinai Medical Center (2) · Gachon University Gil Medical Center (2) · University of Oxford (2) · Ache Laboratorios Farmaceuticos S.A. (1) · Baylor College of Medicine (1) · Brasilia Heart Study Group (1) · Bronx VA Medical Center (1) · Complexa, Inc. (1) · Federal University of Bahia (1) · Fundación Lindavista del Corazón AC (1) · Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (1) · Heidelberg University (1) · Hospital Universitario 12 de Octubre (1) · Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (1)
United States (12) · Brazil (4) · South Korea (4) · Netherlands (2) · United Kingdom (2) · China (1) · Germany (1) · Mexico (1) · Spain (1) · Taiwan (1)
Frank LJ Visseren, MD PhD (2) · Adolfo D Rodriguez-Carrizalez, PhD, MD (1) · Alejandra G Miranda-Diaz, PhD,MD,FACS (1) · Alejandra Meaney, MD, PhD (1) · Andrei C Sposito, MD, PhD (1) · Christie Ballantyne, M.D. (1) · Christopher M Kramer, M.D. (1) · Chu-Huang Chen, M.D., Ph.D. (1) · Colin Baigent (1) · Colin Baigent, FRCP, FFPH (1) · David M Maahs, MD (1) · Francisco Fonseca, physician (1)
PMID 18765432, PMID 38018702, PMID 16749654, PMID 16893434, PMID 18226326, PMID 18376000, PMID 18376001, PMID 18394022, PMID 18670365, PMID 18824462, PMID 19061694, PMID 19075102, PMID 19580719, PMID 19660694, PMID 20487050, PMID 20599002, PMID 21050476, PMID 21120461, PMID 21570685, PMID 21663949, PMID 21699369, PMID 21859750, PMID 21867844, PMID 22108151, PMID 22147903, PMID 22155702, PMID 22293030, PMID 22440214, PMID 23018312, PMID 23279632, PMID 23288881, PMID 23357717, PMID 23728830, PMID 23739650, PMID 23866306, PMID 24780909, PMID 24903982, PMID 25014686, PMID 25048345, PMID 25217488, PMID 25301859, PMID 25438232, PMID 25685360, PMID 26290682, PMID 26330412, PMID 26336957, PMID 26385817, PMID 26486166, PMID 26489804, PMID 26602073
2008 (1), K23DK075360 (1), R01AG021570 (1), R01CA280060 (1), R01HL075792 (1)